Potent and selective inhibition of hepatitis C virus replication by novel phenanthridinone derivatives

Biochemical and Biophysical Research Communications

Volumn 415, Issue 4, 2011, Pages 714-719

  Salim, Mohammed T A ^a   Aoyama, Hiroshi ^b,e   Sugita, Kazuyuki ^b   Watashi, Kouichi ^c   Wakita, Takaji ^c   Hamasaki, Takayuki ^a   Okamoto, Mika ^a   Urata, Yasuo ^d   Hashimoto, Yuichi ^b   Baba, Masanori ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^d National Institute of Infectious Diseases   (Japan)

^e TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

Flavivirus; HCV; JFH1; Phenanthridinone; Replicon cell

Indexed keywords

4 BUTYL 11 (1,1,1,3,3,3 HEXAFLUORO 2 HYDROXYPROPAN 2 YL) 7 METHOXY [1,3]DIOXOLO[4,5 C]PHENANTHRIDIN 5(4H) ONE; 4 BUTYL 11 (1,1,1,3,3,3 HEXAFLUORO 2 HYDROXYPROPAN 2 YL) [1,3]DIOXOLO[4,5 C]PHENANTHRIDIN 5(4H) ONE; 5 BUTYL 2 (1,1,1,3,3,3 HEXAFLUORO 2 HYDROXYPROPAN 2 YL) 3,8 DIMETHOXYPHENANTHRIDIN 6(5H) ONE; HA 718; HA 719; KZ 16; LUCIFERASE; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5A; PHENANTHRIDINE DERIVATIVE; RNA POLYMERASE; UNCLASSIFIED DRUG; VIRUS RNA;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG STRUCTURE; ENZYME ACTIVITY; GENOTYPE; HEPATITIS C VIRUS; HOST CELL; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; REPLICON; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS GENOME; VIRUS INHIBITION; VIRUS REPLICATION; WESTERN BLOTTING;

ANTIVIRAL AGENTS; BENZODIOXOLES; CELL LINE; HEPACIVIRUS; HUMANS; PHENANTHRIDINES; VIRUS REPLICATION;

FLAVIVIRUS; HEPATITIS C VIRUS;

EID: 84855877936     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.10.153     Document Type: Article

References (44)

1. Koziel M., Peters M. Viral hepatitis in HIV infection. N. Engl. J. Med. 2007, 356:1445-1454.
2. Hoofnagle J.H. Course and outcome of hepatitis C. Hepatology 2002, 36:S21-29.
3. Sharma P., Lok A. Viral hepatitis and liver transplantation. Semin. Liver Dis. 2006, 26:285-297.
4. Di Bisceglie A.M., Hoofnagle J.H. Optimal therapy of hepatitis C. Hepatology 2002, 36:S121-127.
5. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Jr Gonçales F.L., Häussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002, 347:975-982.
6. Craxi A., Licata A. Clinical trial results of peginterferons in combination with ribavirin. Semin. Liver Dis. 2003, 23(1):35-46.
7. Choo Q.L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A. Non-B viral hepatitis genome. Science 1989, 244:359-362.
8. Houghton M., Weiner A., Han J., Kuo G., Choo Q.L. Molecular biology of the hepatitis C viruses: implications for diagnosis. Development and control of viral disease. Hepatology 1991, 14:381-388.
9. Suzuki T., Ishii K., Aizaki H., Wakita T. Hepatitis C viral life cycle. Adv. Drug Deliv. Rev. 2007, 59:1200-1212.
10. Lohmann V., Korner F., Koch J.O., Herian U., Theilmann L., Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999, 285:110-113.
11. Wakita T., Pietschmann T., Kato T., Date T., Miyamoto M., Zhao Z., Murthy K., Habermann A., Krausslich H.G., Mizokami M., Bartenschlager R., Liang T.J. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 2005, 11:791-796.
12. Zeisel M.B., Baumert T.F. Production of infectious hepatitis C virus in tissue culture: a breakthrough for basic and applied research. J. Hepatol. 2006, 44:436-439.
13. Bartenschlager R. The hepatitis C virus replicon system: from basic research to clinical application. J. Hepatol. 2005, 43:210-216.
14. Bartenschlager R. Hepatitis C virus molecular clones: from cDNA to infectious virus particles in cell culture. Curr. Opin. Microbiol. 2006, 9:416-422.
15. Brass V., Moradpour D., Blum H.E. Molecular virology of hepatitis C virus (HCV): 2006 update. Int. J. Med. Sci. 2006, 3:29-34.
16. Delang L., Coelmont L., Neyts J. Antiviral therapy for hepatitis C virus: beyond the standard of care. Viruses 2010, 2:826-866.
17. Lange C.M., Sarrazin C., Zeuzem S. Specifically targeted anti-viral therapy for hepatitis C - A new era in therapy. Aliment. Pharmacol. Ther. 2010, 32:14-28.
18. Schinazi R.F., Bassit L., Gavegnano C. HCV drug discovery aimed at viral eradication. J. Viral Hepat. 2010, 17:77-90.
19. Kieffer T.L., Kwong A.D., Picchio G.R. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J. Antimicrob. Chemother. 2010, 65:202-212.
20. Nakamura M., Aoyama A., Salim M.T.A., Okamoto M., Baba M., Miyachi H., Hashimoto Y., Aoyama H. Structural development studies of anti-hepatitis C virus agents with a phenanthridinone skeleton. Bioorg. Med. Chem. 2010, 18:2402-2411.
21. Aoyama H., Sugita K., Nakamura M., Aoyama A., Salim M.T.A., Okamoto M., Baba M., Hashimoto Y. Fused heterocyclic amido compounds as anti-hepatitis C virus agents. Bioorg. Med. Chem. 2011, 19:2675-2687.
22. Goto K., Watashi K., Murata T., Hishiki T., Hijikata M., Shimotohno K. Evaluation of anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporine A, and NIM811. Biochem. Biophys. Res. Commun. 2006, 343:879-884.
23. Ishii N., Watashi K., Hishiki T., Goto K., Inoue D., Hijikata M., Wakita T., Kato N., Shimotohno K. Diverse effects of cyclosporine on hepatitis C virus strain replication. J. Virol. 2006, 80:4510-4520.
24. Windisch M.P., Frese M., Kaul A., Trippler M., Lohmann V., Bartenschlager R. Dissecting the interferon-induced inhibition of hepatitis C virus replication by using a novel host cell line. J. Virol. 2005, 79:13778-13793.
25. Watashi K., Hijikata M., Hosaka M., Yamaji M., Shimotohno K. Cyclosporine A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003, 38:1282-1288.
26. Appel N., Pietschmann T., Bartenschlager R. Mutational analysis of hepatitis C virus nonstructural protein 5A: potential role of differential phosphorylation in RNA replication and identification of a genetically flexible domain. J. Virol. 2005, 79:3187-3194.
27. Ikeda M., Yi M., Li K., Lemon S.M. Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7cells. J. Virol. 2002, 76:2997-3006.
28. Ikeda M., Abe K., Dansako H., Nakamura T., Naka K., Kato N. Efficient replication of a full-length hepatitis C virus genome, Strain O, in cell culture, and development of a luciferase reporter system. Biochem. Biophys. Res. Commun. 2005, 329:1350-1359.
29. Yi M., Lemon S.M. Adaptive mutations producing efficient replication of genotype 1a hepatitis C virus RNA in normal Huh7 cells. J. Virol. 2004, 78:7904-7915.
30. Blight K.J., McKeating J.A., Rice C.M. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J. Virol. 2002, 76:13001-13014.
31. Lohmann V., Hoffmann S., Herian U., Penin F., Bartenschlager R. Viral and cellular determinants of hepatitis C virus RNA replication in cell culture. J. Virol. 2003, 77:3007-3019.
32. Abe K., Ikeda M., Dansako H., Naka K., Kato N. Cell culture-adaptive NS3 mutations required for the robust replication of genome-length hepatitis C virus RNA. Virus Res. 2007, 125:88-97.
33. Rychlowska M., Bieńkowska-Szewczyk K. Hepatitis C - new developments in the studies of the viral life cycle. Acta Biochim. Pol. 2007, 54:703-715.
34. Bukh J., Purcell R.H., Miller R.H. Sequence analysis of the core gene of 14 hepatitis C virus genotypes. Proc. Natl. Acad. Sci. USA 1994, 91:8239-8243.
35. Ohno O., Mizokami M., Wu R.R., Saleh M.G., Ohba K., Orito E., Mukaide M., Williams R., Lau J.Y. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J. Clin. Microbiol. 1997, 35:201-207.
36. Kato T., Date T., Miyamoto M., Furusaka A., Tokushige K., Mizokami M., Wakita T. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 2003, 125:1808-1817.
37. Gao M., Nettles R.E., Belema M., Snyder L.B., Nguyen V.N., Fridell R.A., Serrano-Wu M.H., Langley D.R., Sun J.H., O'Boyle D.R.I.I., Lemm J.A., Wang C., Knipe J.O., Chien C., Colonno R.J., Grasela D.M., Meanwell N.A., Hamann L.G. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010, 465:96-100.
38. Coelmont L., Kaptein S., Paeshuyse J., Vliegen I., Dumont J.M., Vuagniaux G., Neyts J. Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Antimicrob. Agents. Chemother. 2009, 53:967-976.
39. Georgel P., Schuster C., Zeisel M.B., Stoll-Keller F., Berg T., Bahram S., Baumert T.F. Virus-host interactions in hepatitis C virus infection: implications for molecular pathogenesis and antiviral strategies. Trends Mol. Med. 2010, 16:277-286.
40. Suzuki T. A Hepatitis C virus-host interaction involved in viral replication: toward the identification of antiviral targets. Jpn. J. Infect. Dis. 2010, 63:307-311.
41. Suarez-Pinzon W.L., Mabley J.G., Power R., Szabó C., Rabinovitch A. Poly (ADP-ribose) polymerase inhibition prevents spontaneous and recurrent autoimmune diabetes in NOD mice by inducing apoptosis of islet-infiltrating leukocytes. Diabetis 2003, 52:1683-1688.
42. Huang S.H., Xiong M., Chen X.P., Xiao Z.Y., Zhao Y.F., Huang Z.Y. PJ34, an inhibitor of PARP-1, Suppresses cell growth and enhances the suppressive effects of cisplatin in liver cancer cells. Oncol. Rep. 2008, 20:567-572.
43. Abdelkarim G.E., Gertz K., Harms C., Katchanov J., Dirnagl U., Szabó C., Endres M. Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in vitro and in vivo models of stroke. Int. J. Mol. Med. 2001, 7:255-260.
44. Patil S., Kamath S., Sanchez T., Neamati N., Schinazi R.F., Buolamwini J.K. Synthesis and biological evaluation of novel 5(H)-phenanthridin-6-ones, 5(H)-phenanthridin-6-one diketo acid, and polycyclic aromatic diketo acid analogs as new HIV-1 integrase inhibitors. Bioorg. Med. Chem. 2007, 15:1212-1228.